Biosolution Co.Ltd (086820) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biosolution Co.Ltd (086820) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.41 Million ≈ $11.80K USD) by net assets (₩26.31 Billion ≈ $17.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 086820 company net worth for the company's overall valuation and market capitalisation.
Biosolution Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Biosolution Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biosolution Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosolution Co.Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Biosolution Co.Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amotech Co. Ltd
KQ:052710
|
0.021x |
|
Seritage Growth Properties
NYSE:SRG
|
-0.019x |
|
ZHEJIANG SHIBAO H YC 1
F:W4K1
|
N/A |
|
HELIOS FAIRFAX PARTNERS
F:3UD
|
0.061x |
|
Faraday Future Intelligent Electric Inc
NASDAQ:FFIE
|
-0.389x |
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
0.095x |
|
Wonder Electricals Limited
NSE:WEL
|
0.133x |
|
Daesung Ind
KO:128820
|
0.002x |
Annual Cash Flow Conversion Efficiency for Biosolution Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Biosolution Co.Ltd from 2015 to 2024. View current stock price of Biosolution Co.Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩31.26 Billion ≈ $21.18 Million |
₩-2.29 Billion ≈ $-1.55 Million |
-0.073x | -242.66% |
| 2023-12-31 | ₩42.13 Billion ≈ $28.55 Million |
₩2.16 Billion ≈ $1.46 Million |
0.051x | +158.85% |
| 2022-12-31 | ₩43.78 Billion ≈ $29.67 Million |
₩-3.81 Billion ≈ $-2.58 Million |
-0.087x | -4808.31% |
| 2021-12-31 | ₩45.01 Billion ≈ $30.50 Million |
₩83.29 Million ≈ $56.44K |
0.002x | +105.12% |
| 2020-12-31 | ₩46.66 Billion ≈ $31.62 Million |
₩-1.69 Billion ≈ $-1.14 Million |
-0.036x | +33.31% |
| 2019-12-31 | ₩48.10 Billion ≈ $32.59 Million |
₩-2.61 Billion ≈ $-1.77 Million |
-0.054x | -359.07% |
| 2018-12-31 | ₩49.06 Billion ≈ $33.25 Million |
₩1.03 Billion ≈ $695.43K |
0.021x | +217.65% |
| 2017-12-31 | ₩4.42 Billion ≈ $2.99 Million |
₩-78.53 Million ≈ $-53.22K |
-0.018x | +94.74% |
| 2016-12-31 | ₩6.12 Billion ≈ $4.15 Million |
₩-2.07 Billion ≈ $-1.40 Million |
-0.338x | -24.26% |
| 2015-12-31 | ₩7.40 Billion ≈ $5.02 Million |
₩-2.02 Billion ≈ $-1.37 Million |
-0.272x | -- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more